

**Bristol Myers Squibb (BMS) Methodology  
Document in support of the EFPIA transparency  
disclosure code for HCP/HCO transfers of value  
pertaining to 2019**

**Publication date - 30 June 2020**

## Contents

Statement for the disclosure of 2019 data during the COVID-19 pandemic in 2020 .....	3
Commitment to transparency .....	3
Publication of disaggregated 2019 disclosure data on Bristol Myers Squibb company website .....	3
Statement regarding Joint Working Agreements .....	3
Introduction .....	4
Definitions.....	4
Recipients.....	4
Kind of Transfers of Value (TOV) .....	4
Disclosure’s scope .....	6
TOV Timing Approach.....	6
Reportable date.....	6
No Show / Cancellation.....	7
Cross-border activities.....	7
Consent management.....	7
Publication.....	7
Date of publication .....	7
Disclosure platform.....	7
Disclosure language .....	7
Disclosure financial data .....	8
TOV Currency Approach .....	8
VAT.....	8
Scientific Publications.....	8

## ***Statement for the disclosure of 2019 data during the COVID-19 pandemic in 2020***

As part of the pharmaceutical industry's annual disclosure of transfers of value to HCPs, ORDMs and HCOs via the Disclosure UK platform and in order to ensure accuracy of the published data, the ABPI writes to all of the HCPs, ORDMs and HCOs named in companies' disclosure data ahead of its publication on Disclosure UK at the end of June. (Over 20,000 in June 2019)

Given the unprecedented pressure on the NHS and health care professionals in responding to the COVID-19 pandemic, in April 2020 the ABPI and PMCPA agreed that it would not be appropriate for industry to write to HCPs, ORDMs or HCOs to request that disclosure data be reviewed. Doing so would add additional work for NHS professionals at this time. To avoid this, and in-line with guidance provided by the ABPI, Bristol Myers Squibb's 2019 transfer of value data has been published on Disclosure UK in aggregate.

### **Commitment to transparency**

The pharmaceutical industry is committed to preserving the integrity of Disclosure UK and transparency in our interactions with HCPs, ORDMs and HCOs. The ABPI continues to explore how the full disaggregated 2019 data can be submitted to Disclosure UK in line with data from previous years.

### ***Publication of disaggregated 2019 disclosure data on Bristol Myers Squibb company website***

The below link is included to provide access to the disaggregated 2019 disclosure data, per the ABPI Disclosure UK 2019 guidelines:

<https://www.bms.com/gb/about-us/responsibility/transparency/working-with-healthcare-professionals.html>

### ***Statement regarding Joint Working Agreements***

*“Bristol-Myers Squibb Pharmaceuticals Limited (“ BMS”) entered into an Agreement on behalf the BMS-Pfizer Alliance (Pfizer Limited the Alliance Partner)”*

The above statement applies to Joint Working Agreements with the following organisations & beneficiaries:

- North West Coast Academic Health Science Network, Innovation Agency
- Staffordshire Sustainability and Transformation Partnership
- Poole Hospital NHS Foundation Trust (PHFT)
- The Academic Health Science Network for the North East and North Cumbria

## ***Introduction***

The approach to timing, tax and currency aspects of Transfer of Value (TOV) disclosure are not defined by the EFPIA Code. Companies are free to define an appropriate methodology and are obliged to publish it as per the EFPIA Code, Article 23, Section 23.05. BMS, as a member of EFPIA, will fulfill this requirement by publishing this document alongside 2019 transparency disclosure reports where possible. All data in the disclosure report was correct at time of publication.

## ***Definitions***

### **Recipients**

BMS are fully aligned with HCP / HCO scope, adjusted when necessary to accommodate country trade association definitions expected by the market.

**HCO:** Any legal person/entity (i) that is a healthcare, medical or scientific association or organisation (irrespective of the legal or organisational form) such as a hospital, clinic, foundation, university or other teaching institution or learned society (except for POs within the scope of article 21) whose business address, place of incorporation or primary place of operation is in Europe or (ii) through which one or more HCPs provide services.

**HCP:** Any natural person that is a member of the medical, dental, pharmacy or nursing professions or any other person who, in the course of his/her professional activities, may prescribe, purchase, supply, recommend or administer a Medicinal Product and whose primary practice, principal professional address or place of incorporation is in Europe. For the purpose of this Code, the definition of HCPs includes: (i) any official or employee of a government, agency or other organisation (whether in the public or private sector) that may prescribe, purchase, supply, recommend or administer Medicinal Products and (ii) any employee of a Member Company whose primary occupation is that of a practising HCP, but excludes (x) all other employees of a Member Company and (y) a wholesaler or distributor of Medicinal Products.

## ***Kind of Transfers of Value (TOV)***

1. Transfers of Value to an HCO, an amount related to any of the categories set forth below:
  - a. Donations and Grants. Donations and Grants to HCOs that support healthcare, including donations and grants (either cash or benefits in kind) to institutions, organisations or associations that are comprised of HCPs and/or that provide healthcare (governed by Article 12 of the EFPIA Code).

- b. Contribution to costs related to Events. Contribution to costs related to Events, through HCOs or third parties, including sponsorship to HCPs to attend Events, such as:
  - i. Registration fees;
  - ii. Sponsorship agreements with HCOs or with third parties appointed by an HCO to manage an Event; and
  - iii. Travel and accommodation (to the extent governed by Article 10 of the EFPIA Code).
- c. Fees for Service and Consultancy. Transfers of Value resulting from or related to contracts between Member Companies and institutions, organisations or associations of HCPs under which such institutions, organisations or associations provide any type of services to a Member Company or any other type of funding not covered in the previous categories. Fees, on the one hand, and on the other hand Transfers of Value relating to expenses agreed in the written agreement covering the activity will be disclosed as two separate amounts.

## 2. Transfers of Value to an HCP:

- a. Contribution to costs related to Events. Contribution to costs related to Events, such as:
  - i. Registration fees; and
  - ii. Travel and accommodation (to the extent governed by Article 10 of the EFPIA Code).
- b. Fees for Service and Consultancy. Transfers of Value resulting from or related to contracts between Member Companies and HCPs under which such HCPs provide any type of services to a Member Company or any other type of funding not covered in the previous categories. Fees, on the one hand, and on the other hand Transfers of Value relating to expenses agreed in the written agreement covering the activity will be disclosed as two separate amounts.
- c. Fees related to travel visas are not reportable

## 3. R&D transfers of value

R&D transfer include all TOV related to pre-clinical and clinical development, paid to an HCO or an HCP directly or indirectly (for example through a CRO or third party vendor).

All R&D TOV are aggregated by country as a single number based on the recipient's country principal practice address in the disclosure report. In case TOV relating to prospective and retrospective non-interventional studies cannot be distinguished, all non-interventional studies are disclosed on an individual basis under fee for service, where consent allows.

## ***Disclosure's scope***

### **TOV Timing Approach**

#### 1. Assumptions

- a. Timing of a TOV determines assignment to a disclosure period and the date required for value calculations (e.g. currency conversion, tax calculation)

#### 2. Principles

- a. As actual values are relevant for disclosure reporting, the following dates are captured and transferred to the BMS reporting solution
  - i. Financial Payments: Actual payment date
  - ii. Transfer of Value:
    1. One-day interactions: Actual interaction date
    2. Multiple-day interactions: Actual interaction start date
- b. Above dates will be used for both:
  - i. assigning any TOV to the relevant disclosure period
  - ii. performing any TOV value calculations
- c. Multi-year contracts / R&D long term clinical trials: reporting of TOV related to the contract / trial follow the above rules.
- d. Congress closure
  - i. For cases where the actual amount of a TOV has not been collected during the disclosure period, such payments will be attached to the next disclosure period.

### **Reportable date**

The following rules have been used for the reportable dates relating to TOV in BMS.

- In Kind (travel, accommodation, registration fees) : Event start date
- In Cash (sponsorship, donation, fee for service) : Payment date

## **No Show / Cancellation**

For payments or TOV relating to an event that has been cancelled, or the HCP has decided not to attend, BMS will only disclose TOV that have been confirmed as provided to the HCP.

## **Cross-border activities**

Where a TOV is made outside of the recipient's country the TOV will be reported within the country disclosure report based on the recipient's principal practice address.

## ***Consent management***

For countries where consent is required for individual publication at the named level of detail for HCPs and HCOs (for those countries where this is required), BMS has requested consent for disclosure to all recipients (HCPs, and HCOs where applicable).

BMS will only publish the individual recipient details where consent has been positively given (for those countries where consent is required). If an HCP or HCO (in those countries where consent is required) has not given consent or has not responded to the consent request, they will be considered to have not given consent and their data will be aggregated prior to publishing.

## ***Publication***

BMS will follow local country trade association procedures and legislation for reporting publication. When required, BMS will republish a disclosure report.

## **Date of publication**

Publication of each country disclosure report will be aligned to the reporting dates provided by the associated country trade associations.

## **Disclosure platform**

For markets with an external central platform: BMS will publish the disclosure report on the central platform. Where possible this methodology report will accompany the disclosure report.

For markets with no external central platform: BMS will publish the disclosure report on the country specific BMS website in a dedicated transparency section.

This methodological note will be attached to this section

## **Disclosure language**

Disclosure language will be as determined by the country trade association

## ***Disclosure financial data***

### **TOV Currency Approach**

1. The disclosure report in any country will be submitted in the local currency of that country
2. Principles
  - a. No currency conversion or translation is needed, if the transaction currency is the same as the one of the recipient's country of practice (e.g. domestic payments)
  - b. Otherwise currency conversion is required:
    - i. the value of transaction currency is used for a currency conversion as follows:
      1. Financial Payments: the average daily rate of the payment date is used for conversion
      2. Transfer of Value: the average daily rate of the interaction date is used for conversion

### **VAT**

Where possible, BMS discloses the full amount of all Transfers of Value exclusive of VAT. In some instances VAT may not be separable, in these cases, VAT has been included in the disclosure amount.

### ***Scientific Publications***

BMS adheres to laws and industry standards for financial transparency reporting. External Authors of scientific publications receive an in-kind transfer of value when BMS pays a publication agency to provide medical writing and editorial services to the external authors at no cost to them. BMS will report funding for medical writing and editorial services, and payment of congress and journal fees.